605507 国邦医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.3948.39713.64214.67727.500
总资产报酬率 ROA (%)3.9576.31211.12510.84415.777
投入资产回报率 ROIC (%)4.2956.81611.96611.90716.672

边际利润分析
销售毛利率 (%)26.59623.41027.54930.13634.007
营业利润率 (%)16.33513.12818.40417.95122.255
息税前利润/营业总收入 (%)15.31612.17616.91418.53024.374
净利润/营业总收入 (%)13.98111.40316.09215.67519.264

收益指标分析
经营活动净收益/利润总额(%)106.69399.567101.981104.11299.296
价值变动净收益/利润总额(%)3.4673.3782.3271.3060.350
营业外收支净额/利润总额(%)-1.804-0.661-1.665-0.2470.776

偿债能力分析
流动比率 (X)2.2622.2222.7543.9591.456
速动比率 (X)1.6711.6631.9982.8240.954
资产负债率 (%)24.89428.22420.88415.53840.563
带息债务/全部投入资本 (%)18.28221.96214.6928.799--
股东权益/带息债务 (%)445.781354.226578.5331,034.220204.726
股东权益/负债合计 (%)301.491254.135378.870543.618146.558
利息保障倍数 (X)-20.996-14.074-14.22729.75812.531

营运能力分析
应收账款周转天数 (天)40.52040.36034.99833.1510.000
存货周转天数 (天)114.644122.036118.058131.4630.000